NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00300781,Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer,https://clinicaltrials.gov/study/NCT00300781,,COMPLETED,The purpose of this study is to learn whether neratinib is safe and effective in treating women with advanced human epidermal growth factor receptor 2 (HER2) positive breast cancer.,YES,Breast Neoplasms|Neoplasms,DRUG: neratinib,"16-week Progression Free Survival, 16 week progression-free survival (PFS) rate of neratinib in women with human epidermal growth factor receptor 2 (HER2) positive breast cancer, either with prior trastuzumab or no prior trastuzumab therapy, evaluated by independent assessment of tumor scans collected at baseline and then every 8 weeks., From first dose to 16 weeks","Objective Response Rate, Percentage of participants with Partial Response (PR) or Complete Response (CR) by independent assessment of tumor per Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR., From first dose date to progression or last tumor assessment, up to 46 months|Clinical Benefit Rate, Percentage of participants who experienced Complete Response (CR), Partial Response (PR), or Stable Disease (SD) ≥ 24 weeks by independent assessment per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions., From first dose date to progression or last tumor assessment, up to 46 months|Duration of Response, Number of weeks between Complete Response (CR) or Partial Response (PR) and the first date of disease progression (PD) or death per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions, From start date of response to first PD/death, up to 46 months",,"Puma Biotechnology, Inc.",,FEMALE,"ADULT, OLDER_ADULT",PHASE2,136,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,3144A1-201 / B1891012,2006-08-04,2008-04,2018-01-30,2006-03-09,2017-08-10,2018-08-14,"University of Colorado Hospital, Aurora, Colorado, 80045, United States|Midwestern Regional Medical Center, Zion, Illinois, 60099, United States|Louisiana State University, Shreveport, Louisiana, 71103, United States|The Cancer Center at GBMC, Baltimore, Maryland, 21204, United States|Oncology Care Associates, Bethesda, Maryland, 20817, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02115, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02115, United States|Boston University Medical Center, Boston, Massachusetts, 02118, United States|Faulkner Hospital, Boston, Massachusetts, 02130, United States|Norris Cotton Cancer Center Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, 03756, United States|The Cancer Institute of New Jersey, New Brunswick, New Jersey, 08901, United States|The Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, 44195, United States|Virginia Mason Medical Center, Seattle, Washington, 98101, United States|Institut Jules Bordet Unite du Chimiotherapie, Brussels, 1000, Belgium|University Hospital Gasthuisberg, Leuven, 3000, Belgium|St-Augustinus Ziekenhuis Oncology Department, Wilrijk, 2610, Belgium|The Hospital Affiliated Academy Military Medical Science, Chinese People's Liberation Army, Beijing, Beijing, 100071, China|No. 81 Hospital of Chinese People's Liberation Army, Nanjing, Jiangsu, 210002, China|Cancer Hospital Peking Union Medical College, Beijing, 100021, China|Chinese People's Liberation Army General Hospital, Beijing, 100853, China|Institut Gustave ROUSSY Service de Pathologie Mammaire, Villejuif Cedex, 94805, France|Jehangir Clinical Development Centre, Pune, Maharashtra, 411001, India|Deenanath Mangeshkar Hospital, Pune, Maharashtra, 411004, India|Nizam's Institute of Medical Sciences, Hyderabad, Panjagutta, 50082, India|Tata Memorial Centre, Mumbai, Parel, 400012, India|Hospital Regional Lic. Adolfo Lopez Mateos Oncología Médica, Mexico City, 01030, Mexico|Arke Estudios Clínicos S.A. de C.V., Mexico City, 06700, Mexico|Hospital de Especialidades MIG, Mexico City, 07300, Mexico|N.N. Blokhin Russian Cancer Research Center of RAMS, Moscow, 115478, Russian Federation|Medical Radiological Research Center of RAMS, Department of Radiation and Surgical Methods, Obninsk, 249036, Russian Federation|City Oncology Dispensary, Saint Petersburg, 197022, Russian Federation|City Hospital N 31 Oncology Haematology Dept. For Adults, Saint Petersburg, 197110, Russian Federation|Breast Tumor Department, N.N. Petrov Research Institute of Oncology, Saint-Petersburg, 197758, Russian Federation",
